P. Y. Dietrich

Discipline

Psychologie (3) Economies et finances (3) Sociologie (1) Littératures (1) Gestion et management (1)

Type de document

Articles (19) Recensions (5)

Co-auteur

Date

Source

Mot-clé

Treatment (9) Patients (9) Patients (8) Cancer (6) Cancer (6) thérapie (5) analyse (5) cancer (5) Therapeutics (5) Human beings (5) Analysis (5) survie (4) Chemotherapy (4) Survival (4) Chemotherapy (4) taux (3) Care (3) Tumors (3) Months (3) Manufacturers' agents (3) Maintenance (3) Lymphomas (3) Commission merchants (3) administration (2) norme (2) sécurité (2) risque (2) besoin (2) modèle (2) maladie (2)

Documents écrit par P. Y. Dietrich (19) | parle de P. Y. Dietrich (0)

Patients' experiences with cancer care in Switzerland: Results of a multicentre cross-sectional survey.
C. Arditi et al.
Une période de terreur et de défis : quand verrons-nous ce monde meilleur ?
P.Y. Dietrich et al. (18 mai 2022)
Oncologie et pandémie de Covid-19 : les patients au cœur des enjeux.
P.Y. Dietrich et al. (19 mai 2021)
Optimized low-dose combinatorial drug treatment boosts selectivity and efficacy of colorectal carcinoma treatment.
M. Zoetemelk et al.
Une période de craintes et de défis : vers un monde meilleur ?
P.Y. Dietrich et al. (27 mai 2020)
Oncologie : naviguer la pandémie de COVID-19 et garder le cap [Oncology: navigating the COVID-19 Pandemic and Steer the Course]
S. Zimmermann et al. (29 avr. 2020)
Journée du cancer : mobiliser autour de la prévention []
S. Peters et al. (19 févr. 2020)
Prospective validation in epithelial tumors of a gene expression predictor of liver metastasis derived from uveal melanoma.
P. Tsantoulis et al. (20 nov. 2019)
Low 5-year cumulative incidence of post-transplant lymphoproliferative disorders after solid organ transplantation in Switzerland.
R. Steiner et al. (2018)
Hypoxia and antitumor CD8(+) T cells: An incompatible alliance?
R. Vuillefroy de Silly et al. (2016)
Extrachromosomal driver mutations in glioblastoma and low-grade glioma
S. Nikolaev et al. (2014)
Phase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of high-grade glioma.
A.F. Hottinger et al. (2014)
Radioimmunotherapy combined with maintenance anti-CD20 antibody may trigger long-term protective T cell immunity in follicular lymphoma patients.
F. Buchegger et al. (2013)
Erratum to: MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status.
P. Bady et al. (2013)
A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma.
C. Renner et al. (2012)
MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status.
P. Bady et al. (2012)
Frequently asked questions in the medical management of high-grade glioma: a short guide with practical answers.
R. Stupp et al. (2008)
Bevacizumab therapy before autologous stem-cell transplantation for POEMS syndrome
P. Y. Dietrich et al.
Degeneracy of antigen recognition as the molecular basis for the high frequency of naive A2/Melan-a peptide multimer(+) CD8(+) T cells in humans.
V. Dutoit et al. (2002)